Tuesday: FDA panel reviews Merck's Ragwiteck

Share this content:

Merck's prescription allergy medication Ragwitek is going before the FDA Allergenic Products Advisory Committee tomorrow, and the panel's discussion documents indicate the under-the-tongue medication is not associated with serious safety concerns, reports Reuters.

An FDA approval would provide an alternative to injections doctors typically give for pollen and ragweed allergies.

Share this content:
Scroll down to see the next article